Innate Immune Activation to Mediate Tumor Control in Bladder Cancer

Randy F. Sweis, MD

Instructor, Department of Medicine |  University of Chicago

Why is Immunotherapy Ineffective in Bladder Cancer?

Modern immunotherapies in bladder cancer work through blocking “checkpoints”, which are negative regulators of the immune response against cancer. However, only a minority of patients respond, and efficacy depends on the presence preexisting, but suppressed, anti-tumor immune response. This project aims to enhance efficacy of immunotherapies in bladder cancer through stimulating the development of an innate anti- tumor immune response.

Laboratory mouse models will be used to study the effects of innate immune activation in bladder cancer, with a goal of developing new therapeutic strategies to improve responses to immunotherapy.